Who Benefits Most: Clinical Eligibility and Biomarker Considerations GLP-1 therapy is most supported in patients with NAFLD or MAFLD without cirrhosis who have concurrent type 2 diabetes, obesity, or metabolic syndrome
In October 2024, the FDA determined that the tirzepatide injection shortage (covering both Mounjaro and Zepbound) was resolved
The interaction of substances can cause side effects such as severe nausea, hypoglycemia, and gastrointestinal distress
Research shows that semaglutide and tirzepatide work through sustained pathways in your body, meaning consistency and proper scheduling can enhance appetite suppression, blood sugar control, and weight loss outcomes
Yes, and this is a common treatment pathway
What many users don't realize is that dehydration and electrolyte depletion drive most of these symptoms and the right electrolyte strategy can dramatically improve how you feel